Ophthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)
NEW YORK--(BUSINESS WIRE)--Ophthotech enters into an exclusive agreement with Penn and UFRF for rights to negotiate to develop and commercialize novel AAV gene therapies